Moreover, in describing a novel BCL3 inhibitor with anti-cancer properties in models of breast cancer [111], we have reported on the transcriptional responses of a panel of key NFkB-responsive genes to BCL3 inhibition mediated both by siRNA and pharmacologically. Here, NFKB1 is linked to breast carcinoma.